Oncology

Eli Lilly and Company recently announced positive late-stage results in its clinical trial testing a combination of its experimental breast cancer drug and another widely-used treatment.

Cancer-focused continuing education programs seek to enhance cancer care at specialty pharmacies.

The risk of a second cancer remained high even 30 years after treatment.

Progression-free survival with IMMU-132 increases from an average of 3.5 months to 16.6 months in patients with breast cancer.

Top news of the day from across the health care landscape.

Top news of the week in oncology and cancer drug development.

Top news of the day from across the health care landscape.

A combination drug regimen may be the answer to treating acute myeloid leukemia.

Mylan gains global licenses for its biosimilar to trastuzumab (Herceptin).

ATR mutations increase skin cancer tumor growth by modulating the tumor microenvironment.

Improvements in breast cancer patient quality of life and mortality seen over last 30 years.

Patients with small renal masses may be undergo surgery when active surveillance could be beneficial.

Scientists discover a metabolic weakness in advanced breast cancer cells.

High genomic copy loss correlated with metastatic melanoma’s ability to thwart the success of immune checkpoint inhibitors.

Adding pertuzumab (Perjeta) to a breast cancer treatment regimen reduced recurrent disease.

Archival tumor tissue reliably identifies patients with folate receptor alpha-positive ovarian cancer.

Ribociclib plus letrozole shows improved survival in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2) advanced or metastatic breast cancer.

Ribociclib plus letrozole improved progression free survival in patients with HR+/HER2 advanced or metastatic breast cancer.

The FDA has approved Novartis’ Kisqali (ribociclib), in combination with an aromatase inhibitor as initial endocrine-based therapy treatment, for the treatment of breast cancer.

BET-inhibitors and immune-based treatments may improve outcomes in patients with blood cancer.

Neoadjuvant chemotherapy decreased recurrence and increased survival in African American patients.

Melanoma survivors more likely to limit sun exposure than individuals without a history of skin cancer.

Target may lead to the development of new drugs that inhibit cancer.

A regulatory protein that weakens the immune response to viral RNA presents a new treatment target for cancer.

Extracellular matrix receptors shield cancer cells from harsh environments.

Targeting the immune response to cancer may lead to new immunotherapies.

Compounds demonstrate high cancer-killing activity and low-toxicity in non-tumor cell line.

Targeted and individualized breast cancer treatment is viable.